Beovu (Brolucizumab PFS) 6 mg/0.05ml x 0.165 ml

BEOVU (brolucizumab) is an ophthalmic solution for intravitreal injection, designed to treat neovascular age-related macular degeneration (wet AMD). This 6 mg/0.05ml prefilled syringe supports targeted delivery for retinal conditions. Suitable for patients seeking advanced wet AMD therapy options.

Strength

6 mg/0.05ml x 0.165 ml

Manufacturer / TM Owner

NOVARTIS PHARMA SCHWEIZ

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BEOVU is used to treat neovascular (wet) age-related macular degeneration, a condition causing abnormal blood vessel growth in the retina. It helps slow vision loss by reducing fluid buildup and stabilizing retinal structure. Patients with wet AMD often experience blurred or distorted vision, and BEOVU targets the underlying vascular changes driving this progression.

Side Effects

After injection, BEOVU works locally within the eye to inhibit vascular endothelial growth factor (VEGF), which can reduce swelling and leakage in the retina. Many patients report stabilized or improved vision over time, though individual responses vary. The treatment aims to preserve retinal integrity and slow disease advancement.

Precautions & Warnings

BEOVU should only be administered by a qualified healthcare professional experienced in intravitreal injections. Patients must inform their provider of any eye infections, inflammation, or recent eye surgeries. Proper aseptic technique is critical to minimize infection risk. Follow-up monitoring is essential to assess treatment response and detect potential complications early.

Avoid Interactions

No formal drug interaction studies have been conducted with BEOVU. Since it acts locally within the eye, systemic exposure is minimal. However, caution is advised when combining with other intravitreal therapies or medications affecting blood pressure. Patients using blood thinners should discuss risks with their ophthalmologist before treatment.

Frequently Asked Questions

BEOVU is used to treat wet age-related macular degeneration (wet AMD) by reducing abnormal blood vessel growth in the retina.

BEOVU is given as an intravitreal injection by a healthcare professional, typically in an outpatient setting.

Common side effects may include reduced vision clarity, eye pain, or redness; report any persistent symptoms to your doctor.

Discuss your full medical and eye history with your ophthalmologist to determine if BEOVU is appropriate for your condition.

Treatment frequency varies by patient; your doctor will determine a dosing schedule based on your response to therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.